Anthracyclines in the treatment of early-stage breast cancer: ally or adversary?
Publication
, Journal Article
Lyman, GH
Published in: Cancer Invest
March 2010
Duke Scholars
Published In
Cancer Invest
DOI
EISSN
1532-4192
Publication Date
March 2010
Volume
28
Issue
3
Start / End Page
217 / 219
Location
England
Related Subject Headings
- Oncology & Carcinogenesis
- Neoplasm Staging
- Humans
- Female
- Clinical Trials as Topic
- Chemotherapy, Adjuvant
- Breast Neoplasms
- Antineoplastic Combined Chemotherapy Protocols
- Anthracyclines
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Lyman, G. H. (2010). Anthracyclines in the treatment of early-stage breast cancer: ally or adversary? Cancer Invest, 28(3), 217–219. https://doi.org/10.3109/07357901003640404
Lyman, Gary H. “Anthracyclines in the treatment of early-stage breast cancer: ally or adversary?” Cancer Invest 28, no. 3 (March 2010): 217–19. https://doi.org/10.3109/07357901003640404.
Lyman GH. Anthracyclines in the treatment of early-stage breast cancer: ally or adversary? Cancer Invest. 2010 Mar;28(3):217–9.
Lyman, Gary H. “Anthracyclines in the treatment of early-stage breast cancer: ally or adversary?” Cancer Invest, vol. 28, no. 3, Mar. 2010, pp. 217–19. Pubmed, doi:10.3109/07357901003640404.
Lyman GH. Anthracyclines in the treatment of early-stage breast cancer: ally or adversary? Cancer Invest. 2010 Mar;28(3):217–219.
Published In
Cancer Invest
DOI
EISSN
1532-4192
Publication Date
March 2010
Volume
28
Issue
3
Start / End Page
217 / 219
Location
England
Related Subject Headings
- Oncology & Carcinogenesis
- Neoplasm Staging
- Humans
- Female
- Clinical Trials as Topic
- Chemotherapy, Adjuvant
- Breast Neoplasms
- Antineoplastic Combined Chemotherapy Protocols
- Anthracyclines
- 3211 Oncology and carcinogenesis